Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy

Affiliations

• ¹ Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. g.mohyuddin@hci.utah.edu.
• ² Department of Hematology, Columbia University, New York, NY, USA.
• ³ Flatiron Health, New York, NY, USA.
• ⁴ Department of Medicine, Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
• ⁵ Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
• ⁶ Department of Population Sciences, University of Utah, Salt Lake City, UT, USA.
• ⁷ Department of Oncology, McMaster University, Hamilton, ON, Canada.
• ⁸ Division of Hematology and Oncology, Mayo Clinic in Arizona, Phoenix, AZ, USA.
• ⁹ Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.